80.48 USD
-0.75 (-0.92%)
At close: Feb 9, 2026
80.48 USD
0 (0%)
After Hours: 2/9/2026, 6:06:15 PM
HALO gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. While HALO belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. HALO is growing strongly while it also seems undervalued. This is an interesting combination With these ratings, HALO could be worth investigating further for value and growth investing!.
1. Profitability
1.1 Basic Checks
- In the past year HALO was profitable.
- In the past year HALO had a positive cash flow from operations.
- In the past 5 years HALO has always been profitable.
- Each year in the past 5 years HALO had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 26.81%, HALO belongs to the top of the industry, outperforming 97.71% of the companies in the same industry.
- The Return On Equity of HALO (118.17%) is better than 99.62% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 42.77%, HALO belongs to the top of the industry, outperforming 99.24% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for HALO is in line with the industry average of 18.12%.
- The 3 year average ROIC (17.81%) for HALO is below the current ROIC(42.77%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROIC | 42.77% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
1.3 Margins
- HALO has a Profit Margin of 47.91%. This is amongst the best in the industry. HALO outperforms 98.28% of its industry peers.
- HALO's Profit Margin has declined in the last couple of years.
- HALO's Operating Margin of 59.33% is amongst the best of the industry. HALO outperforms 100.00% of its industry peers.
- HALO's Operating Margin has declined in the last couple of years.
- HALO has a Gross Margin of 84.55%. This is amongst the best in the industry. HALO outperforms 87.19% of its industry peers.
- In the last couple of years the Gross Margin of HALO has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% |
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so HALO is creating value.
- Compared to 1 year ago, HALO has less shares outstanding
- HALO has less shares outstanding than it did 5 years ago.
- HALO has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 5.57 indicates that HALO is not in any danger for bankruptcy at the moment.
- HALO has a better Altman-Z score (5.57) than 74.57% of its industry peers.
- The Debt to FCF ratio of HALO is 2.51, which is a good value as it means it would take HALO, 2.51 years of fcf income to pay off all of its debts.
- HALO's Debt to FCF ratio of 2.51 is amongst the best of the industry. HALO outperforms 93.12% of its industry peers.
- A Debt/Equity ratio of 1.59 is on the high side and indicates that HALO has dependencies on debt financing.
- HALO has a Debt to Equity ratio of 1.59. This is in the lower half of the industry: HALO underperforms 76.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Altman-Z | 5.57 |
ROIC/WACC3.65
WACC11.72%
2.3 Liquidity
- HALO has a Current Ratio of 1.59. This is a normal value and indicates that HALO is financially healthy and should not expect problems in meeting its short term obligations.
- HALO has a worse Current ratio (1.59) than 79.54% of its industry peers.
- A Quick Ratio of 1.37 indicates that HALO should not have too much problems paying its short term obligations.
- The Quick ratio of HALO (1.37) is worse than 80.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 |
3. Growth
3.1 Past
- HALO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.55%, which is quite impressive.
- The Earnings Per Share has been growing by 30.12% on average over the past years. This is a very strong growth
- HALO shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.19%.
- Measured over the past years, HALO shows a very strong growth in Revenue. The Revenue has been growing by 38.95% on average per year.
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
3.2 Future
- The Earnings Per Share is expected to grow by 17.78% on average over the next years. This is quite good.
- HALO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.23% yearly.
EPS Next Y58.04%
EPS Next 2Y40.36%
EPS Next 3Y32.57%
EPS Next 5Y17.78%
Revenue Next Year38.12%
Revenue Next 2Y32.39%
Revenue Next 3Y25.48%
Revenue Next 5Y13.23%
3.3 Evolution
- The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 14.29 indicates a correct valuation of HALO.
- Based on the Price/Earnings ratio, HALO is valued cheaper than 96.37% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 28.06, HALO is valued a bit cheaper.
- With a Price/Forward Earnings ratio of 9.66, the valuation of HALO can be described as very reasonable.
- Based on the Price/Forward Earnings ratio, HALO is valued cheaply inside the industry as 98.28% of the companies are valued more expensively.
- The average S&P500 Price/Forward Earnings ratio is at 27.86. HALO is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.29 | ||
| Fwd PE | 9.66 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, HALO is valued cheaper than 96.56% of the companies in the same industry.
- HALO's Price/Free Cash Flow ratio is rather cheap when compared to the industry. HALO is cheaper than 96.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.71 | ||
| EV/EBITDA | 12.3 |
4.3 Compensation for Growth
- HALO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- HALO has an outstanding profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as HALO's earnings are expected to grow with 32.57% in the coming years.
PEG (NY)0.25
PEG (5Y)N/A
EPS Next 2Y40.36%
EPS Next 3Y32.57%
5. Dividend
5.1 Amount
- No dividends for HALO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
80.48
-0.75 (-0.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03 2025-11-03/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners105.85%
Inst Owner Change-1.53%
Ins Owners0.81%
Ins Owner Change-0.62%
Market Cap9.46B
Revenue(TTM)1.24B
Net Income(TTM)595.49M
Analysts76
Price Target79.56 (-1.14%)
Short Float %11.69%
Short Ratio6.66
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.41%
Min EPS beat(2)3.56%
Max EPS beat(2)19.26%
EPS beat(4)4
Avg EPS beat(4)11.06%
Min EPS beat(4)3.56%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)12.2%
EPS beat(12)10
Avg EPS beat(12)9.54%
EPS beat(16)13
Avg EPS beat(16)9.68%
Revenue beat(2)2
Avg Revenue beat(2)6.93%
Min Revenue beat(2)2.18%
Max Revenue beat(2)11.69%
Revenue beat(4)4
Avg Revenue beat(4)7.01%
Min Revenue beat(4)1.36%
Max Revenue beat(4)12.81%
Revenue beat(8)6
Avg Revenue beat(8)5.71%
Revenue beat(12)7
Avg Revenue beat(12)2.94%
Revenue beat(16)9
Avg Revenue beat(16)2.47%
PT rev (1m)2.63%
PT rev (3m)3.08%
EPS NQ rev (1m)14.96%
EPS NQ rev (3m)13.89%
EPS NY rev (1m)4.46%
EPS NY rev (3m)6.45%
Revenue NQ rev (1m)10.99%
Revenue NQ rev (3m)11.2%
Revenue NY rev (1m)3.21%
Revenue NY rev (3m)5.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.29 | ||
| Fwd PE | 9.66 | ||
| P/S | 7.62 | ||
| P/FCF | 15.71 | ||
| P/OCF | 15.49 | ||
| P/B | 18.78 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.3 |
EPS(TTM)5.63
EY7%
EPS(NY)8.33
Fwd EY10.35%
FCF(TTM)5.12
FCFY6.36%
OCF(TTM)5.2
OCFY6.46%
SpS10.57
BVpS4.28
TBVpS-2.22
PEG (NY)0.25
PEG (5Y)N/A
Graham Number23.3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROCE | 53.28% | ||
| ROIC | 42.77% | ||
| ROICexc | 86.79% | ||
| ROICexgc | N/A | ||
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% | ||
| FCFM | 48.47% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexgc growth 3Y-1.13%
ROICexgc growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score8
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Debt/EBITDA | 0.98 | ||
| Cap/Depr | 10.51% | ||
| Cap/Sales | 0.69% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 101.16% | ||
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 | ||
| Altman-Z | 5.57 |
F-Score8
WACC11.72%
ROIC/WACC3.65
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
EPS Next Y58.04%
EPS Next 2Y40.36%
EPS Next 3Y32.57%
EPS Next 5Y17.78%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
Revenue Next Year38.12%
Revenue Next 2Y32.39%
Revenue Next 3Y25.48%
Revenue Next 5Y13.23%
EBIT growth 1Y54.59%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year61.82%
EBIT Next 3Y38.38%
EBIT Next 5Y15.57%
FCF growth 1Y70.36%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y65.76%
OCF growth 3Y16.96%
OCF growth 5YN/A
HALOZYME THERAPEUTICS INC / HALO FAQ
Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 7 / 10 to HALO.
Can you provide the valuation status for HALOZYME THERAPEUTICS INC?
ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.
Can you provide the profitability details for HALOZYME THERAPEUTICS INC?
HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 8 / 10.
What is the financial health of HALOZYME THERAPEUTICS INC (HALO) stock?
The financial health rating of HALOZYME THERAPEUTICS INC (HALO) is 6 / 10.
Can you provide the expected EPS growth for HALO stock?
The Earnings per Share (EPS) of HALOZYME THERAPEUTICS INC (HALO) is expected to grow by 58.04% in the next year.